**REVIEW OF ZIKA VIRUS**

**Pavan Dhondu Tagad1, Yash Ganesh Kulkarni2 , Mr.Sandesh S. Dahiwal3**

1Student ,Ojas College Of Pharmacy, Jalna -431203, Maharashtra, India

2Student ,Ojas College Of Pharmacy, Jalna -431203, Maharashtra, India

3Assistant Professor & Guide, Ojas College Of Pharmacy, Jalna -431203, Maharashtra, India

**corresponding Author :-**

**Pavan Dhondu Tagad**

1Student ,Ojas College Of Pharmacy, Jalna -431203, Maharashtra, India

1. **ABSTRACT**

The Zika virus (ZIKV) is an arbovirus belonging to the family Flaviviridae and the genus Flavivirus. ZIKV infections in humans were intermittent for fifty years before appearing in the Pacific and the Americas. ZIKV was originally isolated from a nonhuman primate in 1947 and from mosquitoes in 1948 in Africa. The usual method of ZIKV transmission is through mosquito bites. Zika fever has a non-specific clinical appearance that makes it easy to confuse with other infectious disorders, particularly those caused by arboviruses like dengue and chikungunya. Prior to the huge French Polynesian outbreak in 2013 and 2014, when severe neurological problems were documented, and the appearance in Brazil of a dramatically increased rate of severe congenital diseases, ZIKV infection was solely linked to mild illness. microcephaly, a deformity thought to be linked to ZIKV. Zika virus isolation or the identification of ZIKV-specific RNA are required for the laboratory diagnosis of Zika fever. Cross-reactivity among Flavivirus species makes serological diagnosis more challenging. Urban areas in the tropics that are plagued with capable mosquito vectors like Aedes aegypti and Aedes albopictus have a significant potential for ZIKV emergence.

**Keywords:**Zika virus, arbovirus, flavivirus, viruses, emerging infectious diseases, zoonoses, microcephaly, craniofacial abnormalities, mosquitoes, Aedes, review literature as topic

1. **INTRODUCTION**

Zika virus (ZIKV) is a mosquito-borne Flavivirus s belonging to the Flaviviridae family.[1] It was first isolated from a rhesus monkey in the Zika forest of Uganda in 1947.It is closely related to several other flaviviruses that cause global disease, including dengue virus (DENV), yellow fever virus (YFV), Japanese encephalitis virus (JEV), West Nile virus (WNV), and tick-borne encephalitis virus (TBEV) [2]. The virus spreads primarily through the bite of infected Aedes aegypti mosquitoes, and can also be transmitted through sexual intercourse, and during pregnancy, from a mother to her fetus.[3] It was not until 1952 that The first case of infection in humans was described in a 10-year-old female from Nigeria in 1954 [4] In 2007, the first major outbreak of Zika fever took place on the Western Pacific Island of Yap in the Federated States of Micronesia [5]Since then, multiple outbreaks of ZIKV have been reported worldwide. Two larger epidemics affecting over 30,000 people took place in 2013 and 2014 in French Polynesia [6,7].

 In 2016, the World Health Organization declared the ZIKV epidemic as an international health emergency . ZIKV infection is mostly asymptomatic and often causes a self-limiting febrile illness in 20% of adults [8]; however, it has been causally associated with congenital malformations and neurological disorders, the virus has recently raised a “Public Health Emergency of International Concern” due to the dramatic increase in the cases of prenatal microcephaly and Guillain-Barré Syndrome (GBS) in ZIKV endemic regions [9]. Microcephaly is characterized by at least two standard deviation reduction in brain volume intellectual and motor disabilities, and behavioral issues [10]. Multiple development factors, such as genetic, environmental, and infectious exposure, during pregnancy are known to contribute to the onset of prenatal microcephaly.GBS, on the other hand, is a rare autoimmune disorder of the peripheral nervous system which could result in muscle weakness, paralysis, or even death [11].

1. **VIROLOGY OF ZIKV**

ZIKV is an 11 kb positive single-stranded RNA virus with a diameter of approximately 40–60 nm that belongs to Flavivirus genus. ZIKV is related to other flaviviruses, more closely with dengue virus (DENV), Japanese encephalitis virus (JEV), yellow fever virus (YFV), and distantly to West Nile virus (WNV). Two important lineages, African and Asian, were identified based on the phylogenetic analyses (12).

ZIKV genome consists of two non-coding regions and one coding region. The coding region encodes a polyprotein that makes three structural proteins (capsid, envelope, membrane precursor) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5).

The three N-terminal structural proteins, capsid protein (C), precursor of membrane(prM), and envelope protein (E) are the skeletal elements for the formation of virus particles. Among them, C combines with viral genomic RNA to form a nucleocapsid core, whereas prM and E are viral surface glycoproteins that are adsorbed to the host cytoplasmic membrane [13]. The M protein is expressed as a glycosylated prM and attached to thehost-derived lipid envelope, whereas the E protein may or may not be glycosylated and this is a determinant of neuroinvasion, acting to increase both transepithelial and axonaltransportation [14].

The seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) at the C-terminus of the genome that participate in multiple stages and functions of the viral life cycle, such as RNA replication, virus particle assembly, and immune escape.Structure of ZIKV is similar to other flaviviruses, except at Asn180 glycosylation site in glycoproteins that make up the icosahedral shell. The glycosylated moiety at Asn180 was required for viral attachment of host cells and varies among ZIKV strains and flaviviruses (15).

Like other flaviviruses, ZIKV may likely infect host cells by endocytosis after the interaction of virus particles with host cell surface receptors. Receptors such as C-type lectin, phosphatidylserine, T cell immunoglobin and mucin (TIM) and AXL, Tyro3, and Mertk (TAM) are identified as entry factors for various flaviviruses. In case of DENV, AXL receptor was considered as a major receptor for viral entry. AXL activates a cascade of events such as activation of AXL kinase, recruitment of interferon receptor (INFAR), inhibition of innate immune response, and replication of the virus inside the host cells. Role of AXL as a receptor required for the entry of ZIKV is contradictory since in vitro results support and most in vivo mice results question its role as a receptor mediating the viral entry (17,18,19,20,21).

1. **ZIKA VIRUS TRANSMISSION**

ZIKV transmission can be classified into vector-borne and non-vector borne. In vector-borne transmission, several species of Aedes mosquitos were reported. In non-vector borne human transmission, routes such as transplacental transmission, blood transfusion, and sexual transmission were reported (22,23).

**1.VECTOR BORNE TRANSMISSION OR MOSQUITO-BORNE TRANSMISSION**

ZIKV transmission to humans occur primarily through bites of an infected, day-dwelling female Aedes aegypti or Aedes albopictus mosquito, similar to the transmission of chikungunya virus (CHIKV) and DENV.Transmission dynamics of ZIKV via mosquitoes is complex, mainly due to the involvement of several mosquito species in ZIKV maintenance. To date, ZIKV has been isolated from 17 Aedes mosquito species as well as Anopheles gambiae, Anopheles coustani, Culex perfuscus, and Mansonia uniformis mosquitoes (24,25,26). Among these several mosquito types, ZIKV transmission to humans has been Hu only for female Aedes aegypti, Aedes albopictus, A. hensilli (responsible for Yap Island outbreak), and A. polynesiensis (responsible for French Polynesia outbreak) (11).albopictus mosquitoes are suspected of broader transmission of virus due to their extensive geographic distribution in tropical, sub-tropical, and temperate regions. In Americas, A. aegypti and A. albopictus are identified as the major vectors for human transmission (10). It is presumed that uninfected mosquitoes acquire ZIKV through infected humans, although further studies are needed to confirm whether the viral titer of infected humans are sufficient to infect mosquitoes. It was suggested that the incubation period for ZIKV in mosquitoes for viral transmission is ~ 10 days (27). An important strategy to prevent mosquito-borne transmission is avoidance of exposure to mosquitos. When possible, pregnant women should delay the travel to the areas of active ZIKV transmission. If travel is unavoidable, women are encouraged to use insect repellents such as DEET and permethrin.

**2. NON-VECTOR-BORNE**

**A. SEXUAL TRANSMISSION**

ZIKV is also capable of trasmitting through sexual intercourse. Multiple cases of male to female transmission of ZIKV have been reported .Sexual transmission is possible from both asymptomatic and symptomatic infections through genital, oral, and anal intercourse, and male to male, male to female, and female to male contact.(28) Sexual transmission is reported to have occurred up to 44 days after symptom onset; infectious viral particles have been isolated up to 69 days after symptom onset in semen and up to 2 days after symptom onset in the female genital tract.(29,30)Zika virus RNA has been detected for up to 6 months after symptom onset in semen and up to 13 days after symptom onset in the female genital tract,(30) which does not necessarily associate with the presence of infectious virus.(31) Therefore, the exact duration of infectivity of genital fluids is unknown.(30) sexual transmission might play a part in non-endemic areas, the main mode of Zika virus transmission is through mosquito bites.The effect of sexual transmission in endemic areas is impossible to assess because the entire population is exposed to mosquitoes.

**B**. **BLOOD TRANSFUSION-RELATED TRANSMISSION**

During the French Polynesia outbreak, ZIKV RNA was detected in approximately 3% of asymptomatic blood donors (acute phase of infection) thus, making blood transfusion a novel potential mode of ZIKV transmission (32,9).ZIKV transmission via blood transfusion is plausible as ZIKV infections are primarily asymptomatic and blood transfusion-related transmission of other Flaviviruses have been reported (33).The first confirmed case of blood transfusion-related ZIKV transmission has been recently reported in Brazil . To address this issue, on 19 February 2016, the WHO issued strict guidelines for blood transfusion/donation in regions where ZIKV was endemic In multiple countries, donated blood is screened via nucleic acid testing to detect WNV RNA (34).As most infections are asymptomatic, the most effective mitigation strategies to prevent transfusion-transmitted infection are nucleic acid testing of blood donations or pathogen inactivation.(46)


**C. MATERNAL TRANSMISSION**

**i. PRENATAL TRANSMISSION**

Perinatal transmission of Zika virus was first reported during the French Polynesian outbreak in 2013.(22) Intrauterine transmission was subsequently confirmed during the Brazilian outbreak.  ZIKV has reportedly been detected in microcephalic neonates born to mothers with a history of ZIKV infection during pregnancy (22). It is postulated that ZIKV has the ability to cross the placenta and subsequently, infect fetal nervous tissues. The suggested mechanism is supported by the evident detection of ZIKV RNA and antigens in the amniotic fluid, placenta, and fetal brain tissue as well as visualization of ZIKV particles in fetal brain via electron microscopy (87,11,10). It is a known fact that the placenta acts as an effective immunological barrier between the mother and the fetus, protecting the fetus from microorganisms in the mother’s circulation. The mechanism used by ZIKV to circumvent the placental barrier is yet to be discovered .

**ii. NURSING MOTHERS**

ZIKV RNA and infectious viral particles have been detected in high loads in the breast milk of infected mothers (36). This introduces a novel transmission mechanism in which ZIKV transmission occurs from the mother to the nursing child. According to a mother-infant pair study, ZIKV RNA was detected in the breast milk and serum of two mothers and in the serum of their respective infants (22). Particularly, serum sample from one of the infants tested positive via RT-PCR after breastfeeding. However, ZIKV replication was not detected upon inoculation of the breast milk on Vero cells hence, making transmission via breast milk uncertain yet plausible. Other potential confounding mother-tochild ZIKV transmission routes should be further investigated. Flavivirus transmission, such as DENV and WNV, via breast milk have been previously reported (38).

1. **ZIKA VIRUS LIFE CYCLE**

**Fig no1 zika virus life cycle**

Similar to other known flaviviruses, the viral life cycle of ZIKV could be roughly divided into stages of binding, entry, translation, replication, assembly, and release [43].Briefly, the E protein is involved in the attachment of virus to receptors on the host cell membrane, and the virus is internalized through endocytosis that is mediated by clathrin proteins in the acid pH environment [20,44].

Several cell surface receptors facilitate ZIKV viral entry, such as Tyro3, DC-SIGN, AXL, and TIM-1 [45]. Subsequently, fusion of viral membrane with endosome membrane occurs, the positive-strand viral genomic RNA releases from nucleocapsid into cytoplasm, and the synthesis of negative-strand genomic RNA using viral positive-strand genome as template by RdRp [9].

On surface of endoplasmic reticulum, the negative-strand RNA is used to synthesize new viral positive-strand genomes and viral mRNAs, which are further translated into viral polyproteins via host machinery. The resulting polyprotein is cleaved into the three nonstructural and seven structural proteins by the viral protease as mentioned above [42].

The newly-synthetized positive RNAs could be recruited for further activities of translation/replication or incorporated into the virions, which initiates their assembly [46]. Immature virions are assembled in the endoplasmic reticulum and transfer to the Golgi apparatus through budding formaturation, until their final release into the extracellular space [15,46].

Virions attach to the cell surface receptors and subsequently enter cells by receptor-mediated endocytosis and are internalized into clathrin-coated vesicles. Endosome acidification triggers conformational changes, fusion of viral membrane with endosome membrane, and particle disassembly and the viral genomic RNA is released from nucleocapsid into the cytoplasm. The ssRNA then is translated into a single polyprotein that is further processed co-translationally and post-translationally by viral and cellular proteases. This cleavage makes three structural proteins and seven nonstructural proteins. Viral genome replication initiates with negative-strand

RNA synthesis, and further serves as a template for the synthesis of the positive-strand genomic RNA. Virus assembly take places in the endoplasmic reticulum (ER) surface by budding, and immature virus particles travel along the host secretory pathway through the trans-Golgi network,

where virion maturation occurs followed by release from the cell via exocytosis. Additionally, the below table shows where the inhibitor/antivirals of ZIKV act during the ZIKV life cycle. Life cycle of ZIKV. Virions attach to the cell surface receptors and subsequently enter cells by receptor-mediated endocytosis and are internalized into clathrin-coated vesicles. Endosome acidification triggers conformational changes, fusion of viral membrane with endosome membrane,and particle disassembly and the viral genomic RNA is released from nucleocapsid into the cytoplasm.

The ssRNA then is translated into a single polyprotein that is further processed co-translationally and post-translationally by viral and cellular proteases. This cleavage makes three structural proteins and seven nonstructural proteins. Viral genome replication initiates with negative-strand RNA synthesis, and further serves as a template for the synthesis of the positive-strand genomic RNA. Virus assembly take places in the endoplasmic reticulum (ER) surface by budding, and immature virus particles travel along the host secretory pathway through the trans-Golgi network, where virion maturation occurs followed by release from the cell via exocytosis. Additionally, the below table shows where the inhibitor/antivirals of ZIKV act during the ZIKV life cycle.

1. **ZIKV-ASSOCIATED NEUROLOGICAL DISORDERS**

#### **MICROCEPHALY**

1. **GUILLAIN-BARRÉ SYNDROME**
2. **MICROCEPHALY**

Microcephaly is a neurological condition in which the brain of a baby does not develop properly, causing the head to be smaller than normal (39,40).

It is divided into two types:

(1) primary or congenital microcephaly, which is present in utero or at birth; and

(2) secondary or postnatal microcephaly, which develops after birth (41).

While primary microcephaly is likely caused by a decrease in the number of neurons produced during neurogenesis, secondary microcephaly is presumably caused by a reduction in the number of dendritic processes and synaptic connections. Microcephaly can be caused by a variety of genetic mutations, peri- and post-natal brain injuries, teratogenic agents, and congenital infectionsThe ZIKV outbreak in Brazil in 2016 had received much attention because of the surge of ZIKV-associated microcephaly cases, suspecting a possible association. At first a link between ZIKV and microcephaly was not widely accepted and alternate proposals for a causative agent included pesticides and a bovine-like viral diarrhea virus [42], but a number of lines of evidence subsequently supported the association. Firstly epidemiological studies supported the association showing that microcephaly was associated with ZIKV infection during pregnancy, particularly when the infection took place in the [first trimester](https://www.sciencedirect.com/topics/medicine-and-dentistry/first-trimester-pregnancy) [[43](https://www.sciencedirect.com/science/article/pii/S1876034119303120" \l "bib0110)].

Secondly, ZIKV was recovered from the brain of a foetus medically aborted for reasons of microcephaly [[44](https://www.sciencedirect.com/science/article/pii/S1876034119303120" \l "bib0115)], and thirdly experimental evidence showed that ZIKV was able to infect human neural progenitor cells [[45](https://www.sciencedirect.com/science/article/pii/S1876034119303120" \l "bib0120)].Animal model systems also provided data supporting the association between ZIKV infection and microcephaly [46]. Further supporting evidence of an association between [Zika virus](https://www.sciencedirect.com/topics/medicine-and-dentistry/zika-virus) infection of pregnant women was provided after a retrospective review of data from French Polynesia [[47](https://www.sciencedirect.com/science/article/pii/S1876034119303120" \l "bib0135)], as well as an increase in the occurrence of microcephaly and other [birth defects](https://www.sciencedirect.com/topics/medicine-and-dentistry/congenital-malformation) in babies born in other countries or territories which had experienced the introduction on ZIKV such as Columbia [49], Puerto Rico , and Mexico.

1. **GUILLAIN–BARRÉ SYNDROME (GBS)**

is one of the new complications and manifestations of ZIKV infection [49]. GBS is a serious and life threatening neurological disorder eventually resulting in respiratory failure characterized by progressive muscular weakness [50].GBS is an autoimmune demyelinating disorder that causes reduced signal transmissions, progressive muscle weakness, and paralysis.

(GBS) is a rapid-onset [muscle weakness](https://en.m.wikipedia.org/wiki/Paralysis) caused by the [immune system](https://en.m.wikipedia.org/wiki/Immune_system) damaging the [peripheral nervous system](https://en.m.wikipedia.org/wiki/Peripheral_nervous_system).[[51]](https://en.m.wikipedia.org/wiki/Guillain%E2%80%93Barr%C3%A9_syndrome#cite_note-NIH2016-3) Typically, both sides of the body are involved, and the initial symptoms are changes in sensation or pain often in the back along with muscle weakness, beginning in the feet and hands, often spreading to the arms and upper body.[[51]](https://en.m.wikipedia.org/wiki/Guillain%E2%80%93Barr%C3%A9_syndrome#cite_note-NIH2016-3)The symptoms may develop over hours to a few weeks.[[51]](https://en.m.wikipedia.org/wiki/Guillain%E2%80%93Barr%C3%A9_syndrome#cite_note-NIH2016-3) During the acute phase, the disorder can be life-threatening, with about 15% of people developing weakness of the [breathing muscles](https://en.m.wikipedia.org/wiki/Respiratory_system) and, therefore, requiring [mechanical ventilation](https://en.m.wikipedia.org/wiki/Mechanical_ventilation). Some are affected by [changes in the function](https://en.m.wikipedia.org/wiki/Dysautonomia) of the [autonomic nervous system](https://en.m.wikipedia.org/wiki/Autonomic_nervous_system), which can lead to dangerous abnormalities in [heart rate](https://en.m.wikipedia.org/wiki/Heart_rate) and [blood pressure](https://en.m.wikipedia.org/wiki/Blood_pressure).

In those with severe weakness, prompt treatment with [intravenous immunoglobulins](https://en.m.wikipedia.org/wiki/Intravenous_immunoglobulin) or [plasmapheresis](https://en.m.wikipedia.org/wiki/Plasmapheresis), together with supportive care, will lead to good recovery in the majority of cases.[[51]](https://en.m.wikipedia.org/wiki/Guillain%E2%80%93Barr%C3%A9_syndrome#cite_note-NIH2016-3) Recovery may take weeks to years, with about a third having some permanent weakness. Globally, death occurs in approximately 7.5% of those affected. Guillain–Barré syndrome is rare, at 1 or 2 cases per 100,000 people every year. Both sexes and all parts of the world have similar rates of disease.The syndrome is named after the French [neurologists](https://en.m.wikipedia.org/wiki/Neurologist) [Georges Guillain](https://en.m.wikipedia.org/wiki/Georges_Guillain) and [Jean Alexandre Barré](https://en.m.wikipedia.org/wiki/Jean_Alexandre_Barr%C3%A9), who, together with French physician [André Strohl](https://en.m.wikipedia.org/wiki/Andr%C3%A9_Strohl), described the condition in 1916.[53,[54]](https://en.m.wikipedia.org/wiki/Guillain%E2%80%93Barr%C3%A9_syndrome#cite_note-Eldar2014-7)

#### **OTHER COMPLICATIONS ASSOCIATED WITH ZIKV INFECTIONS**

### **Eye Diseases**

ZIKV causes mild eye infections in adults with symptoms such as conjunctivitis and uveitis in adults (59,60). However, ZIKV-related eye infections in infants are much severe and include blindness, optic neuritis, chorioretinal atrophy, bilateral iris coloboma, and intraretinal hemorrhages. ZIKV-related microcephaly case studies revealed ocular abnormalities in 10 out of 29 infants (63). ZIKV is found to cause panuveitis in mice and sheds from tears (61). The presence of ZIKV in eyes suggests that eyes may act as one of the reservoir hosts for ZIKV following the acute phase of infection.

### **Meningoencephalitis**

ZIKV-related meningoencephalitis can occur rarely. To date, it was observed only in a single case of 81-year-old male returned from ZIKV endemic area (62). Brain infection resembling meningoencephalitis was seen in immunodeficient mice subjected to intravenous ZIKV injections (64). These shreds of evidence suggest a possible association of ZIKV infections to meningoencephalitis and thus merit further studies in this direction.

1. **SYMPTOMS**

Not everyone who is infected will experience symptoms. These are the symptoms that can appear within 2 weeks of being bitten:

* Fever
* Rash
* Joint pain
* Muscle pain
* Headache
* Conjunctivitis (red eyes)

The symptoms are usually mild and only affect 1 out of 5 infected people.

1. **ZIKV DIAGNOSIS**

An accurate and timely diagnosis of ZIKV infection is essential to choose correct treatment strategies. Clinical diagnosis of ZIKV is difficult because of its symptoms overlap with other arboviruses and cross-reactivity to other faviviral antibodies present in the serum at the time of infection. Laboratory approval is necessary for diagnosis of Zika infection considering that there is no pathognomonic presentation that differentiates Zika fever from other infections as well as congenital ZIKV infection from other etiologies of congenital abnormalities

 Current diagnosis of ZIKV infection includes :-

1. Reverse Transcription Polymerase Chain Reaction (RT-PCR)
2. Immunoglobulin (Ig) G/M Enzyme-Linked Immunosorbent Assay (ELISA)
3. Plaque Reduction Neutralization Test (PRNT)
4. **RT-PCR**

Real-time and conventional RT-PCR are the most common approaches utilized in diagnostic.Molecular methods to detect ZIKV-specific nucleic acids by RT-PCR are preferred during the acute phase of ZIKV infection because of its high specificity and sensitivity. ZIKV DNA by RT-PCR can be detected up to 2 weeks of symptom onset in urine and saliva samples, and up to 2 months in blood samples. RT-PCR methods that detect either conserved regions of the viral genome or multiplex assays that allows simultaneous detection of ZIKV, DENV, and CHIKV have been developed (63,64,65,67,68,69,70).the ZIKV envelope genes (prM/E protein coding regions) are targeted for amplification due to their unique characteristics which allow differentiation from other Flaviviruses (33). Two specific sets of primers for the Asian ZIKV strain have been tested and established (66). To further increase specificity, the use of TaqMan probe is recommended . Commercial kits (for research purposes) for ZIKV RNA detection via RT-PCR have recently entered the market (71).

Peripheral blood samples are predominantly used for PCR-based assays (70). However, RT-PCR on blood and serum samples is associated with reduced sensitivity due to low viremia in humans (72). More recently, detection of higher viral RNA load over a longer duration was reported in urine and semen samples . Related studies coherently reported detection of higher DENV and WNV RNA load over a longer duration in urine samples, as compared blood serum. ZIKV RNA has also been reported to be detected in the saliva of infected individuals,often more readily compared to blood samples. The choice and combination of samples chosen for is highly dependent on the stage of infection . It is recommended to perform RT-PCR on both blood and saliva/urine samples in order to increase test sensitivity, during the late stage of infection (73). In addition, alternative sampling of urine or saliva reduces invasiveness and hence, is advantageous for diagnosis in neonates and infants (71). For prenatal testing, amniotic fluid is predominantly collected molecular analysis. A positive RT-PCR for ZIKV RNA is suggestive of intrauterine infection and plausible reduction in fetus fitness (10). Ultimately, products of ZIKV RNA specific RT-PCR amplification, regardless of sample source, cam also be sequenced and aligned against established ZIKV genome sequences for confirmation (32).

**2.** **ELISA -** **Enzyme-Linked Immunosorbent Assay**

IgM/IgG ELISA involves the detection of ZIKV-specific antibodies in the serum (74). IgM antibodies are known to develop within a few days post onset of symptoms and can last up to 3 months. IgG antibodies on the other hand, develop after IgM and can last from a few months to years.

**3. Plaque Reduction Neutralization Test (PRNT)**

PRNT is used for virus-specific neutralizing antibody titer quantification (75). The test is reported to have improved specificity compared to ELISA hence, it is often used in addition to ELISA to rule-out false positive antibody response (75,70). The PRNT was used in addition to ELISA for diagnosis and confirmation of ZIKV in 185 patients during the French Polynesia outbreak. To perform the PRNT, firstly, serum sample from the patient was diluted and mixed with a suspension of ZIKV. Subsequently, the mixture was poured over a monolayer of cells, often Vero or LLC-MK2 cell lines . The cells were subsequently covered with a thin layer of agar to avoid viral movement. PRNT against other Flaviviruses are concurrently performed as a control (75). At least a 4-fold increase in ZIKV-specific neutralizing antibody titer is recommended for confirmation of ZIKV infection . However, interpretation of results could be complicated if high Flavivirus background is observed in the patient, often due to history of vaccination against Flaviviruses (66,75).

1. **TREATMENT OF ZIKV**

In ZIKV infection, individuals should have adequate water intake, ample rest and treat pain and fever with liquid solutions. If the symptoms aggravate, they should look for counselling and therapeutic consideration. Tere are no specifc medications or vaccine available to treat or prevent ZIKV infections until now; only medications for symptomatic relief can be considered such as paracetamol to relieve pain and fever associated with this infection [77]. Nonsteroidal anti-infammatory drugs (NSAIDs) should be avoided and individuals should seek medical advice before taking additional medication if they are already taking medicines for another medical condition [78]. Homeopathy is a worthy treatment option in ZIKV infection as it proved to be efective in Japanese encephalitis virus which is included in the same genus like Zika virus [79]. Treatment with belladonna efcaciously reduced the severity of Japanese encephalitis virus infection [81]. Atropa belladonna plant belongs to family Solanaceae [80]. It has been efective in numerous medical conditions having great commercial signifcance as a major source of alkaloids, mainly scopolamine and hyoscyamine that are pharmaceutical bioactive compounds [80]1. Belladonna is native to North Africa, Western Asia and Europe. In Atropa belladonna majority of alkaloidal contents are present in ripe fruit and green leaves. It has been used from ancient times in order to treat various human ailments including menstrual disorders, headache, peptic ulcer, infammation and histaminic reaction [82]. Ultra diluted belladonna concentrations like 1:10 or 1:100 are used in homeopathy and they are recommended for management of all the infectious diseases and illnesses [83].Eupatorium is a naturally occurring pharmaceutical homeopathic compound efective against the symptoms of ZIKV disease, so it can be utilized as prophylactic treatment against ZIKV infection [84]. Eupatorium perfoliatum, Rhustox and Atropa belladonna are the homeopathic prescriptions that may be utilized for ZIKV infection treatment. Tese medicinal agents are efective against the symptoms of ZIKV infection [85]. During epidemics homeopathic pharmaceuticals are more efective in reduction of mortality and morbidity as compare to conventional system of medicines [86]. One of the utmost momentous features of ayurvedic structure is that they are natural substances and free from side efects and there is no scientifc evidence of danger for human use [87]. It is a primordial medical science that contains herbal medicines of natural origin with minimal side efects. Tinospora cordifolia is a herb and utilized for years as potential immunomodulator and efective natural remedy for viral disease of any nature. It boosts up the immune system and make body resistant enough to fght against infections. Teses herbs potentiate phagocytic abilities of macrophages [87]. Intestinal sickness, urinary tract infections, dengue and swine infuenza are efectively treated by the astringent characteristics of these ayurvedic plants so they might also be efective for ZIKV [78].Beside homeopathic and ayurveda medicines, engineering approaches were also applied to develop peptidetherapeutics and support the potential of a brain-penetrating peptide to treat neurotropic viral infections. Terapeutic treatment protected against mortality and evidently lessened symptoms, neuroinfammation and viral loads, furthermore mitigated microgliosis, neurodegeneration and brain damage [87]. Current medical recommendations are directed towards resolving symptoms and not the actual infection; however, ZIKV treatments and vaccines are in development. In 2016, WHO enlist all publicly afrmed commercial, government and academic-led projects focused at ZIKV interventions, together with vaccines [90]. Te list encompasses numerous approaches, comprising vaccines via purifed inactivated virus, Virus-like particles (VLP), protein subunits, DNA and live recombinant attenuated viruses. Since April 2019, no vaccines have been permitted for clinical usage, though utmost were in the clinical stages of development [91,92].

1. **Conclusion :-**

Alarming concerns have been generated by the recent ZIKV epidemics in the Americas over the potential link between ZIKV infection and unexpected clinical symptoms, such as premature. GBS and microcephaly. Due to a lack of standardised ZIKV detection methods and a limited understanding of ZIKV transmission dynamics, it has been challenging to assess the risks and severity of ZIKV infection. To this purpose, evidence from published papers suggesting a possible connection between prenatal microcephaly and ZIKV infection and GBS has been compiled in this review. This review also included recent developments in ZIKV transmission and detection and emphasised the significance of comprehending transmission dynamics for the later creation of a quick, inexpensive, and expedient ZIKV detection assay and control strategy. The development of strict surveillance systems (for people and mosquitoes) is advocated as a final preventive measure, especially in tropical areas where the likelihood of a ZIKV outbreak is higher.Case-control studies could be used in future research to examine the relationship between ZIKV infection and microcephaly/GBS and to rule out any potential etiological confounding variables. Future research might potentially look into more potential ZIKV reservoirs and go deeper into the host cellular response and ZIKV pathogenesis pathways in order to produce a reliable detection assay, a ZIKV vaccine, and antiviral treatments.

1. **Reference**
2. Lindenbach, B.D., Thiel, H.J., Rice, C.M., 2007. Flaviviridae: the viruses and their replication. In: Knipe, D.M., Howley, P.M., Griffin, D.E., Lamb, R.A., Martin, M.A., Roizman, B., B.-H. Song et al. / Journal of Neuroimmunology 308 (2017) 50–64 61 Straus, S.E. (Eds.), Fields Virology, fifth ed. Lippincott Williams & Wilkins Publishers, Philadelphia, PA, pp. 1101–1152.
3. Pierson, T.C.; Diamond, M.S. The continued threat of emerging flaviviruses. Nat. Microbiol. 2020, 5, 796–812. [CrossRef] [PubMed]
4. Abrams, R.P.M., Solis, J., 2017. Therapeutic approaches for zika virus infection of the nervous system. Neurotherapeutics 14 (4), 1027–1048. https://doi.org/10.1007/ s13311-017-0575-2.
5. Macnamara FN: [Zika viru2.lku2’+\53s: a report on three cases of human infection during an epidemic of jaundice in Nigeria](https://dx.doi.org/10.1016/0035-9203(54)90006-1). Trans R Soc Trop Med Hyg. 1954, 48:139-145. [10.1016/0035-9203(54)90006-1](https://dx.doi.org/10.1016/0035-9203(54)90006-1)
6. Duffy MR, Chen TH, Hancock WT, et al.: [Zika virus outbreak on Yap Island, Federated States of Micronesia](https://dx.doi.org/10.1056/NEJMoa0805715). N Engl J Med. 2009, 360:2536-2543. [10.1056/NEJMoa0805715](https://dx.doi.org/10.1056/NEJMoa0805715)
7. Cao-Lormeau VM, Roche C, Teissier A, et al.: [Zika virus, French Polynesia, South Pacific, 2013](https://dx.doi.org/10.3201/eid2006.140138). Emerg Infect Dis. 2014, 20:1085-1086. [10.3201/eid2006.140138](https://dx.doi.org/10.3201/eid2006.140138)
8. Musso D, Nhan T, Robin E, et al.: [Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014](https://dx.doi.org/10.2807/1560-7917.es2014.19.14.20761). Euro Surveill. 2014, 19: 20761. [10.2807/1560-7917.es2014.19.14.20761](https://dx.doi.org/10.2807/1560-7917.es2014.19.14.20761)
9. Weaver, S.C.; Costa, F.; Garcia-Blanco, M.A.; Ko, A.I.; Ribeiro, G.S.; Saade, G.; Shi, P.Y.; Vasilakis, N. Zika virus: History, emergence, biology, and prospects for control. Antivir. Res. 2016, 130, 69–80. [CrossRef] [PubMed]
10. Basarab, M., Bowman, C., Aarons, E. J., and Cropley, I. (2016). Zika virus. BMJ 352:i1049. doi: 10.1136/bmj.i1049
11. Petersen, L. R., Jamieson, D. J., Powers, A. M., and Honein, M. A. (2016). Zika virus. N. Engl. J. Med. 374, 1552–1563. doi: 10.1056/NEJMra1602113
12. Lazear, H. M., and Diamond, M. S. (2016). Zika virus: new clinical syndromes and its emergence in the western hemisphere. J. Virol. 90, 4864–4875. doi: 10.1128/JVI.00252-16
13. Faye O, Freire CC, Iamarino A, Faye O, de Oliveira JV, Diallo M, Zanotto PM, Sall AA (2014) Molecular evolution of Zika virus during its emergence in the 20(th) century. PLoS Negl Trop Dis 8(1):e2636. https://doi.org/10.1371/journal.pntd.0002636
14. Heinz, F.X.; Stiasny, K. The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis. Microbiol. Mol. Biol. Rev. 2017, 81, e00055-16. [CrossRef]
15. Neal, J.W. Flaviviruses are neurotropic, but how do they invade the CNS? J. Infect. 2014, 69, 203–215. [CrossRef] [PubMed]
16. Hilgenfeld, R. Zika virus NS 1, a pathogenicity factor with many faces. EMBO J. 2016, 35, 2631–2633.
17. Sirohi D, Chen Z, Sun L, Klose T, Pierson TC, Rossmann MG, Kuhn RJ (2016) The 3.8 a resolution cryo-EM structure of Zika virus. Science 352(6284):467470. https://doi.org/10.1126/science.aaf5316
18. Hamel R, Dejarnac O, Wichit S, Ekchariyawat P, Neyret A, Luplertlop N, Perera-Lecoin M, Surasombatpattana P, Talignani L, Thomas F, Cao-Lormeau VM, Choumet V, Briant L, Despres P, Amara A, Yssel H, Misse D (2015) Biology of Zika virus infection in human skin cells. J Virol 89(17):88808896. https://doi.org/10.1128/JVI.00354-15
19. Hastings AK, Yockey LJ, Jagger BW, Hwang J, Uraki R, Gaitsch HF, Parnell LA, Cao B, Mysorekar IU, Rothlin CV, Fikrig E, Diamond MS, Iwasaki A (2017) TAM receptors are not required for Zika virus infection in mice. Cell Rep 19(3):558–568. https://doi.org/10.1016/j.celrep.2017.03.058
20. Nowakowski TJ, Pollen AA, Di Lullo E, Sandoval-Espinosa C, Bershteyn M, Kriegstein AR (2016) Expression analysis highlights AXL as a candidate Zika virus entry receptor in neural stem cells. Cell Stem Cell 18(5):591–596. https://doi.org/10.1016/j.stem.2016.03.012
21. Tabata T, Petitt M, Puerta-Guardo H, Michlmayr D, Wang C, Fang-Hoover J, Harris E, Pereira L (2016) Zika virus targets different primary human placental cells, suggesting two routes for vertical transmission. Cell Host Microbe 20(2):155–166. <https://doi.org/10.1016/j.chom.2016.07.002>
22. Wang L, Valderramos SG, Wu A, Ouyang S, Li C, Brasil P, Bonaldo M, Coates T, Nielsen-Saines K, Jiang T, Aliyari R, Cheng G (2016) From mosquitos to humans: genetic evolution of Zika virus. Cell Host Microbe 19(5):561–565. <https://doi.org/10.1016/j.chom.2016.04.006>.
23. Besnard M, Lastere S, Teissier A, Cao-Lormeau V, Musso D (2014) Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. Euro Surveill 19
24. Foy BD, Kobylinski KC, Chilson Foy JL, Blitvich BJ, Travassos da Rosa A, Haddow AD, Lanciotti RS, Tesh RB (2011) Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg Infect Dis 17(5):880–882. https://doi.org/10.3201/eid1705.101939
25. Ayres CF (2016) Identification of Zika virus vectors and implications for control. Lancet Infect Dis 16(3):278–279. https://doi.org/10.1016/S1473-3099(16)00073-6
26. Saiz JC, Vazquez-Calvo A, Blazquez AB, Merino-Ramos T, Escribano-Romero E, Martin-Acebes MA (2016) Zika virus: the latest newcomer. Front Microbiol 7:496
27. Slavov SN, Otaguiri KK, Kashima S, Covas DT (2016) Overview of Zika virus (ZIKV) infection in regards to the Brazilian epidemic. Braz J Med Biol Res 49:e5420
28. Boorman JP, Porterfield JS (1956) A simple technique for infection of mosquitoes with viruses; transmission of Zika virus. Trans R Soc Trop Med Hyg 50(3):238–242. <https://doi.org/10.1016/0035-9203(56)90029-3>
29. Davidson A, Slavinski S, Komoto K , Rakshan J , Weiss D.Suspected female-to-male sexual transmission of Zika virus—New York City, 2016.MMWR Morb Mortal Wkly Rep. 2016; 65: 716-717
30. Penot P, Brichler S, Guilleminot J,et al. Infectious Zika virus in vaginal secretions from an HIV-infected woman, France, August 2016.Euro Surveill. 2017; 22: 30444
31. Moreira J, Peixoto TM, Siqueira AM, Lamas CC. Sexually acquired Zika virus: a systematic review.Clin Microbiol Infect. 2017; (publishedonlineJan3.)https://doi.org/10.1016/j.cmi.2016.12.07
32. Baud D, Musso D, Vouga M, Alves MP, Vulliemoz N Zika virus: a new threat to human reproduction. Am J Reprod Immunol. 2017; 77: e12614
33. Musso, D., Nhan, T., Robin, E., Roche, C., Bierlaire, D., Zisou, K., et al.(2014). Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia. Euro Surveill. 19:20761.doi: 10.2807/1560-7917.ES2014.19.14.20761
34. Marano, G., Pupella, S., Vaglio, S., Liumbruno, G. M., and Grazzini, G. (2016).Zika virus and the never-ending story of emerging pathogens and transfusion medicine. Blood Transfus. 14, 95–100. doi: 10.2450/2015.0066-15
35. O’Brien, S. F., Scalia, V., Zuber, E., Hawes, G., Alport, E. C., Goldman, M.,et al. (2010). West Nile virus in 2006 and 2007: the Canadian Blood Services’experience. Transfusion 50, 1118–1125. doi: 10.1111/j.1537-2995.2009.02550.
36. Musso D, Broult J, Bierlaire D, Lanteri M, Aubry M. Prevention of transfusion-transmitted Zika virus in French Polynesia, nucleic acid testing versus pathogen inactivation. ISBT Sci Ser. 2016; 12: 254-259
37. Dupont-Rouzeyrol, M., Biron, A., O’Connor, O., Huguon, E., and Descloux, E. (2016). Infectious Zika viral particles in breastmilk. Lancet 387, 1051. doi: 10.1016/s0140-6736(16)00624-3
38. Besnard, M., Lastère, S., Teissier, A., Cao-Lormeau, V. M., and Musso, D. (2014). Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. Euro Surveill. 19:20751. doi: 10.2807/1560-7917.ES2014.19.13.20751
39. Ognjan, A., Boulton, M. L., Somsel, P., Stobierski, M. G., Stoltman, G., Downes, K., et al. (2002). Possible West Nile virus transmission to an infant through breast-feeding-Michigan. MMWR Morb. Mortal. Wkly. Rep. 51, 877–878
40. Klase, Z.A., Khakhina, S., Schneider Ade, B., Callahan, M.V., Glasspool-Malone, J., Malone, R.,2016. Zika fetal neuropathogenesis: etiology of a viral syndrome. PLoS Negl. Trop. Dis.10, e0004877.
41. Panchaud, A., Stojanov, M., Ammerdorffer, A., Vouga, M., Baud, D., 2016. Emerging role of Zika virus in adverse fetal and neonatal outcomes. Clin. Microbiol. Rev. 29, 659–694
42. Alcantara, D., O'Driscoll, M., 2014. Congenital microcephaly. Am. J. Med. Genet. C. Semin. Med. Genet. 166C, 124–139.
43. M. Triunfol. New data back early hypothesis for infectious microcephaly Lancet Infect Dis, 16 (2016), pp. 1008-1009
44. T.V. de Araujo, L.C. Rodrigues, R.A. de Alencar Ximenes, D. de Barros Miranda-Filho, U.R. Montarroyos, A.P. de Melo, et al.Association between Zika virus infection and microcephaly in Brazil, January to May, 2016: preliminary report of a case-control study Lancet Infect Dis (2016)
45. J. Mlakar, M. Korva, N. Tul, M. Popovic, M. Poljsak-Prijatelj, J. Mraz, et al.Zika virus associated with microcephalyN Engl J Med (2016)
46. H. Tang, C. Hammack, C. Ogden Sarah, Z. Wen, X. Qian, Y. Li, et al.Zika virus infects human cortical neural progenitors and attenuates their growthCell Stem Cell, 18 (2016), pp. 587-590
47. F.T. Goodfellow, B. Tesla, G. Simchick, Q. Zhao, T. Hodge, M.A. Brindley, et al.Zika virus induced mortality and microcephaly in chicken embryos Stem Cells Dev, 25 (2016), pp. 1691-1697
48. S. Cauchemez, M. Besnard, P. Bompard, T. Dub, P. Guillemette-Artur, D. Eyrolle-Guignot, et al. Association between Zika virus and microcephaly in French Polynesia, 2013–15: a retrospective study Lancet, 387 (2016), pp. 2125-2132
49. O. Pacheco, M. Beltran, C.A. Nelson, D. Valencia, N. Tolosa, S.L. Farr, et al. Zika virus disease in Colombia - preliminary report N Engl J Med (2016)
50. Pithadia AB, Kakadia N. Guillain–Barré syndrome (GBS). Pharmacol Rep. 2010;62:220–32.
51. [Guillain–Barré Syndrome Fact Sheet"](https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Guillain-Barr%C3%A9-Syndrome-Fact-Sheet). NIAMS. June 1, 2016. [Archived](https://web.archive.org/web/20160805044252/http:/www.ninds.nih.gov/disorders/gbs/detail_gbs.htm) from the original on 5 August 2016. Retrieved 29 August 2022.
52. Sejvar JJ, Baughman AL, Wise M, Morgan OW (2011). ["Population incidence of Guillain-Barré syndrome:asystematicreviewandmetaanalysis"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703046). Neuroepidemiology. **36** (2):12333. [doi](https://en.m.wikipedia.org/wiki/Doi_(identifier)):[10.1159/000324710](https://doi.org/10.1159%2F000324710). [PMC](https://en.m.wikipedia.org/wiki/PMC_(identifier)) [5703046](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703046). [PMID](https://en.m.wikipedia.org/wiki/PMID_(identifier)) [21422765](https://pubmed.ncbi.nlm.nih.gov/21422765).
53. 6-van Doorn PA, Ruts L, Jacobs BC (October 2008). "Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome". The Lancet. Neurology. **7** (10): 939–50. [doi](https://en.m.wikipedia.org/wiki/Doi_(identifier)):[10.1016/S1474-4422(08)70215-1](https://doi.org/10.1016%2FS1474-4422%2808%2970215-1). [PMID](https://en.m.wikipedia.org/wiki/PMID_(identifier)) [18848313](https://pubmed.ncbi.nlm.nih.gov/18848313). [S2CID](https://en.m.wikipedia.org/wiki/S2CID_(identifier)) [9307245](https://api.semanticscholar.org/CorpusID:9307245).
54. 7-Eldar AH, Chapman J (April 2014). "Guillain Barré syndrome and other immune mediated neuropathies: diagnosis and classification". Autoimmunity Reviews. **13** (4–5): 525–30. [doi](https://en.m.wikipedia.org/wiki/Doi_(identifier)):[10.1016/j.autrev.2014.01.033](https://doi.org/10.1016%2Fj.autrev.2014.01.033). [PMID](https://en.m.wikipedia.org/wiki/PMID_(identifier)) [24434363](https://pubmed.ncbi.nlm.nih.gov/24434363).
55. Benzekri R, Belfort R, Jr, Ventura CV, de Paula Freitas B, Maia M, Leite M, Labetoulle M, Rousseau A (2017) Ocular manifestations of Zika virus: what we do and do not know. J Fr Ophtalmol
56. Furtado JM, Esposito DL, Klein TM, Teixeira-Pinto T, da Fonseca BA (2016) Uveitis associated with Zika virus infection. N Engl J Med 375(4):394–396. <https://doi.org/10.1056/NEJMc1603618>
57. Miner JJ, Sene A, Richner JM, Smith AM, Santeford A, Ban N, Weger-Lucarelli J, Manzella F, Ruckert C, Govero J, Noguchi KK, Ebel GD, Diamond MS, Apte RS (2016b) Zika virus infection in mice causes panuveitis with shedding of virus in tears. Cell Rep 16(12):3208–3218. <https://doi.org/10.1016/j.celrep.2016.08.079>
58. Mecharles S, Herrmann C, Poullain P, Tran TH, Deschamps N, Mathon G, Landais A, Breurec S, Lannuzel A(2016) Acute myelitis due to Zika virus infection. Lancet 387(10026):1481. <https://doi.org/10.1016/S0140-6736(16)00644-9>
59. de Paula Freitas B, de Oliveira Dias JR, Prazeres J, Sacramento GA, Ko AI, Maia M, Belfort R, Jr (2016) Ocular findings in infants with microcephaly associated with presumed zika virus congenital infection in Salvador, Brazil. JAMA Ophthalmol
60. Fernandes NC, Nogueira JS, Ressio RA, Cirqueira CS, Kimura LM, Fernandes KR, Cunha MS, Souza RP, Guerra JM (2016) Experimental Zika virus infection induces spinal cord injury and encephalitis in newborn Swiss mice. Exp Toxicol Pathol
61. Corman VM, Rasche A, Baronti C, Aldabbagh S, Cadar D, Reusken CBEM, Pas SD, Goorhuis A, Schinkel J, Molenkamp R, Kümmerer BM, Bleicker T, Brünink S, Eschbach-Bludau M, Eis-Hübinger AM, Koopmans MP, Schmidt-Chanasit J, Grobusch MP, de Lamballerie X, Drosten C, Drexler JF (2016) Clinical comparison, standardization and optimization of Zika virus molecular detection [submitted]. Bull World Health Organ 94(12):880–892. https://doi.org/10.2471/BLT.16.175950
62. Faye O, Faye O, Dupressoir A, Weidmann M, Ndiaye M, Alpha Sall A (2008) One-step RT-PCR for detection of Zika virus. J Clin Virol 43(1):96–101. https://doi.org/10.1016/j.jcv.2008.05.005
63. Faye O, Faye O, Diallo D, Diallo M, Weidmann M, Sall AA (2013) Quantitative real-time PCR detection of Zika virus and evaluation with field-caught mosquitoes.Virol J 10(1):311. https://doi.org/10.1186/1743-422X-10-311
64. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, Stanfield SM, Duffy MR (2008) Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis 14(8):1232–1239. https://doi.org/10.3201/eid1408.080287
65. Nicolini AM, McCracken KE, Yoon JY (2017) Future developments in biosensors for field-ready Zika virus diagnostics. J Biol Eng 11(1):7. https://doi.org/10.1186/s13036-016-0046-z.
66. Pyke AT, Daly MT, Cameron JN, Moore PR, Taylor CT, Hewitson GR, Humphreys JL, Gair R (2014) Imported zika virus infection from the cook islands into australia, 2014. PLoS Curr 6.
67. Tappe D, Rissland J, Gabriel M, Emmerich P, Gunther S, Held G, Smola S, Schmidt-Chanasit J (2014) First case of laboratory-confirmed Zika virus infection imported into Europe, November 2013. Euro Surveill 19
68. Waggoner JJ, Gresh L, Mohamed-Hadley A, Ballesteros G, Davila MJ, Tellez Y, Sahoo MK, Balmaseda A, Harris E, Pinsky BA (2016) Single-reaction multiplex reverse transcription PCR for detection of Zika, chikungunya, and dengue viruses. Emerg Infect Dis 22(7):1295–1297. https://doi.org/10.3201/eid2207.160326
69. Charrel, R. N., Leparc-Goffart, I., Pas, S., Lamballerie, X., Koopmans, M., and Reusken, C. (2016). State of knowledge on Zika virus for an adequate laboratory response. Bull. World Health Organ. doi: 10.2471/BLT.16.171207. [Epub ahead of print].
70. Vorou, R. (2016). Zika virus, vectors, reservoirs, amplifying hosts, and their potential to spread worldwide: what we know and what we should investigate urgently. Int. J. Infect. Dis. 48, 85–90. doi: 10.1016/j.ijid.2016.05.014
71. Gourinat, A., O’Connor, O., Calvez, E., Goarant, C., and Dupont-Rouzeyrol, M. (2015). Detection of Zika virus in urine. Emerg. Infect. Dis. 21, 84–86.doi: 10.3201/eid2101.140894
72. Huzly, D., Hanselmann, I., Schmidt-Chanasit, J., and Panning, M. (2016). High specificity of a novel Zika virus ELISA in European patients after exposure to different Flaviviruses. Euro Surveill. 21:30203.doi: 10.2807/1560-7917.ES.2016.21.16.30203
73. Rabe, I. B., Staples, J. E., Villanueva, J., Hummel, K. B., Johnson, J. A.,Rose, L., et al. (2016). Interim guidance for itnerpretation of Zika virus antibody test results. MMWR Morb. Mortal. Wkly. Rep. 65, 543–546.doi: 10.15585/mmwr.mm6521e1
74. Hayes, E. B. (2009). Zika virus outside Africa. Emerg. Infect. Dis. 15, 1347–1350.
75. Saxena SK, Elahi A, Gadugu S, Prasad AK. Zika virus outbreak: an overview of the experimental therapeutics and treatment. VirusDisease. 2016;27:111–5.doi: 10.3201/eid1509.090442
76. European Centre for Disease Prevention and Control. Rapid risk assessment: ZIKV infection outbreak, Brazil and the Pacifc region. 25 May 2015.http://ecdc.europa.eu/en/publications/Publications/rapidrisk-assessment Zika%20virus-south-america-Brazil-2015.
77. Bandyopadhyay B, Das S, Sengupta M, Saha C, Das KC, Sarkar D, et al. Decreased intensity of Japanese encephalitis virus infection in chick chorioallantoic membrane under infuence of ultradiluted Belladonna

extract. Am J Infect Dis. 2010;6:24–8.

1. Rowson JM. The pharmacognosy of Atropa belladonna LINN. J Pharm Pharmacol. 1950. https://doi.org/10.1111/j.2042-7158.1950.tb12925.x.
2. Rajput H. Efects of Atropa belladonna as anti-cholinergic. Nat Prod Chem Res. 2013;1:104.
3. Rita P, Animesh DK. An updated overview on Atropa belladonna L. Int Res J Pharm. 2011;2:11–7.
4. Ulbricht C, Basch E, Hammerness P, Vora M, Wylie J, Woods J. An evidence-based systematic review of Belladonna by the Natural Standard Research Collaboration. J Herb Pharmacother. 2004;4:61–90.
5. Calvet G, Aguiar RS, Melo ASO, Sampaio SA, de Filippis I, Fabri A, et al. Detection and sequencing of Zika virus from amniotic fuid of fetuses with microcephaly in Brazil: a case study. Lancet Infect Dis. 2016;16:653–60.
6. Bousta D, Soulimani R, Jarmouni I, Belon P, Falla J, Froment N, et al. Neurotropic, immunological and gastric efects of low doses of Atropa belladonna L., Gelsemium sempervirens L. and Poumon histamine in stressed mice. J Ethnopharmacol. 2001;74:205–15.
7. Ullman D. Controlled clinical trials evaluating the homeopathic treatment of people with human immunodefciency virus or acquired immune defciency syndrome. J Altern Complement Med. 2003;9:133–41.
8. Patwardhan B, Vaidya ADB, Chorghade M. Ayurveda and natural products drug discovery. Curr Sci. 2004;86:789–99.
9. Mittal J, Sharma MM, Batra A. Tinospora cordifolia: a multipurpose medicinal plant—a review. J Med Plants Stud. 2014;2:32–47.
10. Jackman JA, Costa VV, Park S, Real ALC, Park JH, Cardozo PL, et al. Therapeutic treatment of Zika virus infection using a brain-penetrating antiviral peptide. Nature Mater. 2018;17:971–7.
11. Quanquin N, Wang L, Cheng G. Potential for treatment and a Zika virus vaccine. Curr Opin Pediatr. 2017;29:114–21.
12. Fernandez E, Diamond MS. Vaccination strategies against Zika virus. Curr Opin Virol. 2017;23:59–67.
13. Abbink P, Stephenson KE, Barouch DH. Zika virus vaccines. Nat Rev Microbiol. 2018;16:594–600.
14. Ekins S, Mietchen D, Cofee M, Stratton TP, Freundlich JS, Freitas-Junior L, et al. Open drug discovery for the Zika virus. F1000Res. 2016;5:150.